Advertisements



Amarin: New Vascepa Prescriptions Grow After REDUCE-IT"s Topline Results

Amarin: New Vascepa Prescriptions Grow After REDUCE-IT"s Topline Results.....»»

Category: topSource: seekingalphaNov 9th, 2018

Why Amarin Shares Are Exploding

Amarin shares absolutely skyrocketed on Monday after the company announced topline results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT. Needless to say, the results were very........»»

Category: blogSource: 247wallstSep 24th, 2018

Amarin Trades Down After Release Of Late-Stage Vascepa Trial Results

Amarin Corporation plc (NASDAQ: AMRN) shares were falling Monday following the presentation of detailed primary results from the the late-stage REDUCE-IT study that evaluated Vascep read more.....»»

Category: blogSource: benzingaNov 12th, 2018

Amarin"s Reduce-It results viewed favorably by doctors, says Citi

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 13th, 2019

Amarin: Vascepa"s Strong Growth Reflects The Positive Reactions From Doctors To REDUCE-IT

Amarin: Vascepa"s Strong Growth Reflects The Positive Reactions From Doctors To REDUCE-IT.....»»

Category: topSource: seekingalphaFeb 20th, 2019

Amarin: In Good Position To Capitalize On Exceptional REDUCE-IT Results

Amarin: In Good Position To Capitalize On Exceptional REDUCE-IT Results.....»»

Category: topSource: seekingalphaDec 10th, 2018

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association Conference Call (Transcript)

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association Conference Call (Transcript).....»»

Category: topSource: seekingalphaNov 13th, 2018

Amarin Goes From Solid To Speculative After Full REDUCE-IT Trial Results Released

Amarin Goes From Solid To Speculative After Full REDUCE-IT Trial Results Released.....»»

Category: topSource: seekingalphaNov 12th, 2018

Amarin's REDUCE-IT Trial: Something Fishy? - Seeking Alpha

STATAmarin's REDUCE-IT Trial: Something Fishy?Seeking AlphaAMRN provided an update on the REDUCE-IT trial of Vascepa; the NEJM provided an online article a.....»»

Category: topSource: googlenewsNov 11th, 2018

Amarin"s Stock Soars as Fish Oil Drug Lowers Heart Risks

Amarin (AMRN) shares soar on positive results from a cardiovascular outcomes study on Vascepa. Shares of Amarin Corporation p.....»»

Category: personnelSource: nytSep 27th, 2018

42 Stocks Moving In Monday"s Mid-Day Session

Gainers Amarin Corporation plc (NASDAQ: AMRN) shares jumped 232.4 percent to $9.94 after the company's REDUCE-IT cardiovascular study of Vascepa in LDL-C patients met its primary endpoint. read more.....»»

Category: blogSource: benzingaSep 24th, 2018

Amarin"s REDUCE-IT study on-track to report results before end of September

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 26th, 2018

Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations

REDUCE-ITâ„¢ Study On-Track for Reporting Top-Line Results by the End of September 2018 Management to.....»»

Category: earningsSource: benzingaAug 1st, 2018

Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations

REDUCE-IT Study On-Track for Reporting Top-Line Results.....»»

Category: earningsSource: benzingaMay 2nd, 2018

Amarin: Waiting For REDUCE-IT Results

Amarin: Waiting For REDUCE-IT Results.....»»

Category: topSource: seekingalphaApr 11th, 2018

Amarin: Update To Standards Of Medical Care In Diabetes Gives Vascepa A Boost

Amarin: Update To Standards Of Medical Care In Diabetes Gives Vascepa A Boost.....»»

Category: topSource: seekingalphaApr 3rd, 2019

Amarin"s Vascepa granted priority review status from Health Canada

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 29th, 2019

Amarin submits sNDA to FDA for new Vascepa indication for cardiovascular risk

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 28th, 2019

Supernus Pharmaceuticals (SUPN) Presents SPN-812 P304 Phase III Topline Data Results - Slideshow

Supernus Pharmaceuticals (SUPN) Presents SPN-812 P304 Phase III Topline Data Results - Slideshow.....»»

Category: topSource: seekingalphaMar 28th, 2019

ADA endorsement a "big score" for Amarin"s Vascepa, says Stifel

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 28th, 2019

Seattle Genetics, Astellas Pharma announce topline results of EV-201 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 28th, 2019